The Medicines Company (Nasdaq: MDCO) saw its share price drop by nearly 4% to $38.65 on Wednesday morning after announcing a setback on its clinical dyslipidemia research.
Its programs were investigating MDCO-216 (containing APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor), and the USA-based biotech’s hopes to end its research early have been scuppered by inconclusive results.
The USA-based company announced that a planned, interim analysis of the first 40 randomized patients completing treatment in the MILANO-PILOT study of MDCO-216 has been reviewed by the study’s independent data monitoring committee.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze